University of Medicine and Dentistry of New Jersey
Trial Pipeline
Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department
NCT00856232
Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia
NCT00391677
Pain and Sensory Changes Assessment in HIV+ Patients
NCT00422695
Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression
NCT00356304
Oxcarbazepine Versus Placebo in Childhood Autism
NCT00467753
Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients
NCT01095276
Etanercept With Tacrolimus for Psoriasis
NCT00134394
Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers
NCT00143988
Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer
NCT00176579
Comparison of Three Electroconvulsive Therapy (ECT) Techniques for the Treatment of Major Depression
NCT00069407
Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
NCT00176592
Expression of Tuberculosis in the Lung
NCT00201253
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for University of Medicine and Dentistry of New Jersey Shows
According to the ClinicalTrials.gov registry, University of Medicine and Dentistry of New Jersey is linked to 12 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 12 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Medicine and Dentistry of New Jersey reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Medicine and Dentistry of New Jersey is Depression with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.